Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
IZEA Q1 2026 Earnings Call - Enterprise Pivot Delivers $18.9M Profit Swing Despite Revenue Decline
IZEA completed its deliberate exit from low-margin SMB work to focus exclusively on enterprise clients, a strategic reset that generated an $18.9 million net profit swing in 2025. While Q1 2026 revenu...
- Strategic Pivot Complete: IZEA finished its exit from the SMB segment, transitioning fully to an enterprise-focused model. This reset resulted in a massive $18.9 million net profit swing in 2025 and increased average revenue per account by 33%.
- Revenue Decline Due to Transition: Q1 2026 revenue fell to $6.6 million from $8.0 million in the prior year. Management attributes this entirely to the runoff of non-core SMB business and timing delays with enterprise accounts, not a loss of demand.
- Enterprise Growth Outpacing Market: Despite the revenue dip, IZEA's enterprise portfolio has grown at a healthy double-digit rate over the last 12 months, surpassing overall industry growth. New wins include Hulu, ASICS, and Garanimals.
- +7 more takeaways
TELA Bio Q1 2026 Earnings Call - Fully Resorbable Hernia Portfolio Launches Amid European Surge and Board Refresh
TELA Bio reported a modest 3% revenue increase to $19.1 million in Q1 2026, but the underlying commercial engine is shifting gears. The company launched OviTex LTR, a fully resorbable reinforcement po...
- TELA Bio reported Q1 2026 revenue of $19.1 million, a 3% increase year-over-year, with OviTex revenue at $12.6 million and international sales up 41% to $3.7 million.
- The company launched OviTex LTR, a fully resorbable tissue-based hernia repair portfolio, priced comparably to existing products to capture surgeons seeking alternatives to permanent synthetic meshes.
- U.S. commercial operations are now fully staffed with over 90 territory managers, including 19 new greenfield territories, shifting focus from hiring to execution and density.
- +7 more takeaways
Atea Pharmaceuticals Q1 2026 Earnings Call - HCV Phase III Enrollment Nears Completion, HEV Program Advances
Atea Pharmaceuticals reported a strong Q1 2026, driven by near-complete enrollment in its global HCV Phase III trials and progress on a new HEV program. The company has $256 million in cash, securing ...
- HCV Phase III Enrollment Milestones: C-BEYOND (North America) is fully enrolled with over 880 patients, while C-FORWARD (global) is 95% enrolled, with top-line data expected mid-year and year-end respectively.
- Strong Financial Position: Atea holds $256 million in cash and marketable securities as of March 31, 2026, extending its cash runway through 2027 to fund ongoing HCV and HEV programs.
- HEV Program Advancement: AT-587, a first-in-class direct-acting antiviral for chronic hepatitis E, has completed CTA-enabling studies and is on track for a first-in-human study mid-year, targeting a $750M-$1B annual market.
- +7 more takeaways
5E Advanced Materials Q3 FY2026 Earnings Call - Secures First Offtake Agreement, Advances High-Value Boron Products
5E Advanced Materials delivered a pivotal third quarter for fiscal 2026, marking its first major commercial milestone with a long-term offtake heads agreement for 7,500 tons of boric acid annually, wi...
- Secured first offtake heads agreement for 7,500 tons of boric acid annually, with optionality to increase to 10,000 tons, featuring fixed pricing, annual escalation, and a five-year term with automatic renewal.
- CEO Paul Weibel highlighted a successful customer roadshow in March, meeting with 12 end users and distributors, revealing strong domestic urgency for a resilient, reliable boron supply chain.
- Developed stable, free-flowing metaboric acid with approximately 80% B2O3 equivalent content, positioning 5E to capture higher margins between standard boric acid and boron oxide.
- +7 more takeaways
Evolv Technologies Q1 2026 Earnings Call - Raised 2026 Revenue Outlook on Purchase Subscription Mix and eXpedite Traction
Evolv Technologies delivered a strong first quarter, with revenue jumping 45% year-over-year to $46.3 million, driven by a shift toward purchase subscriptions that front-load product revenue and a rec...
- Revenue surged 45% year-over-year to $46.3 million, beating prior guidance and reflecting strong end-market demand.
- Annual recurring revenue (ARR) grew 20% to $127.3 million, signaling durable subscription momentum.
- Adjusted EBITDA margin expanded to 8.5% from 6.4% in the prior year period, despite gross margin compression from a fulfillment model shift.
- +7 more takeaways
OptimizeRx Q1 2026 Earnings Call - Revenue Guidance Cut Amid MFN Headwinds, But AI and Programmatic DSP Integration Offer Long-Term Upside
OptimizeRx delivered a solid Q1 2026, beating consensus on the top and bottom line, but management cut full-year revenue guidance to $95M-$100M due to short-term disruptions from Most Favored Nation (...
- Revenue Guidance Cut: Full-year 2026 revenue guidance lowered to $95M-$100M due to MFN-related disruption and cautious pharma budgeting, though adjusted EBITDA guidance of $21M-$25M is maintained.
- Q1 Results Beat Consensus: Q1 revenue was $19.8M (-10% YoY) but adjusted EBITDA rose 120% to $3.3M, beating estimates. Non-GAAP net income doubled to $2.7M.
- MFN Headwinds Persist: Contracted revenue remains 15-20% behind prior year levels, primarily driven by shorter contract durations as pharma clients react to Most Favored Nation pricing dynamics.
- +9 more takeaways
Kura Oncology Q1 2026 Earnings Call - KOMZIFTI Launch Exceeds Expectations with 40% New Patient Share
Kura Oncology’s first full quarter as a commercial entity is off to a strong start. KOMZIFTI (ziftomenib) generated $5.8 million in net product revenue, driven by 85 new patient starts across 60 activ...
- KOMZIFTI generated $5.8 million in net product revenue in Q1 2026, surpassing management's initial expectations for the first full quarter of launch.
- The company secured 85 new patient starts across approximately 60 activated accounts, capturing roughly 40% of the new patient market share in the NPM1-mutant AML space despite being second-to-market.
- Physicians are actively switching patients from competing menin inhibitors to KOMZIFTI, signaling early product differentiation based on efficacy, safety, and dosing convenience.
- +7 more takeaways
MaxCyte Q1 2026 Earnings Call - Core Revenue Misses, but Restructuring and New Products Signal Turnaround
MaxCyte reported $9.7 million in Q1 2026 revenue, missing expectations as core revenue fell 25% year-over-year to $6.2 million due to inventory management at its largest customer and discontinued SPL ...
- Total revenue of $9.7 million missed expectations, driven by a 25% YoY decline in core revenue to $6.2 million due to inventory management at its largest customer and discontinued SPL programs.
- SPL program-related revenue rose 62% YoY to $3.4 million, including a $3 million regulatory milestone from a clinical customer dosing in a registrational study.
- Operating expenses fell $7 million YoY to $14.3 million, reflecting the full impact of 2025 restructuring and cost efficiency actions, with no meaningful OpEx growth expected going forward.
- +7 more takeaways
Nyxoah Q1 2026 Earnings Call - U.S. Revenue Acceleration and Reimbursement Clarity Drive Q2 Outlook
Nyxoah reported a strong start to 2026, with Q1 worldwide net revenue rising 13% sequentially to EUR 6.4 million, driven by a 25% surge in U.S. sales. The company achieved its first full quarter of U....
- Q1 2026 worldwide net revenue reached EUR 6.4 million, up 13% sequentially, with U.S. net revenue surging 25% to EUR 4.3 million.
- U.S. commercial execution is accelerating, with 40 active sales reps now covering 200 of the 400 targeted high-volume accounts.
- Surgeon adoption is deepening, with 207 total surgeons trained and 91 active accounts (surgeons trained and VAC committee approved) out of 125 targeted sites.
- +7 more takeaways
Verrica Pharmaceuticals First Quarter 2026 Earnings Call - YCANTH Sales Accelerate, Pipeline Advances
Verrica Pharmaceuticals reported accelerating demand for its molluscum treatment YCANTH in the first quarter of 2026, with U.S. revenue rising 25.4% year-over-year to $4.3 million and dispensed applic...
- U.S. YCANTH revenue rose 25.4% year-over-year to $4.3 million in Q1 2026, driven by a 51.3% increase in dispensed applicator units to 15,302.
- YCANTH achieved a new record for monthly dispensed applicator units in March 2026, with demand continuing to accelerate into April.
- Torii Pharmaceutical launched YCANTH in Japan for molluscum treatment in February 2026, following regulatory approval, marking a key international milestone.
- +7 more takeaways